文献速递系统性红斑狼疮

狼疮肾炎缓解后免疫抑制治疗的撤药研究

Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

该研究评估了狼疮肾炎(LN)患者达到缓解后停用免疫抑制治疗(IS)的复发率及预测因素。缓解后维持IS至少3年、抗疟药维持治疗、停药时年龄较大及缓解持续时间>3年与复发风险降低相关。

要点

  • LN患者缓解后停用IS可行,但需满足缓解至少3年并维持抗疟药治疗。
  • 停用IS后复发率为22.9%,多数复发患者重启治疗可重新缓解。
  • 缓解后维持IS≥3年、抗疟药使用、停药年龄大及缓解>3年均降低复发风险。

核心结论

  • LN患者缓解至少3年且使用抗疟药维持治疗时停用IS是可行的。
  • 发生复发的患者经适当治疗可重新达到缓解。

研究设计与样本

  • 回顾性队列研究,纳入1980年至2020年间经活检证实的LN并接受IS治疗的患者。
  • 共238例经肾活检并接受IS治疗的LN患者纳入分析。

主要发现

  • 平均(标准差)随访116.5(78)个月,19例(22.9%)复发,其中8/19为肾脏复发。
  • 14/19(73.7%)复发患者重启治疗后重新达到缓解。

关键数值与推荐

  • 缓解定义为血肌酐正常、蛋白尿<0.5 g/24 h、尿沉渣不活跃且无肾外SLE活动,并维持稳定免疫抑制和/或抗疟药治疗和/或泼尼松≤5mg/天。
  • 缓解后维持IS至少3年的患者复发风险最低(OR 0.284,95% CI:0.093,0.867;P=0.023)。
  • 多因素分析显示抗疟药维持治疗(OR 0.194,95% CI:0.038,0.978;P=0.047)、停药时年龄(OR 0.93,95% CI:0.868,0.997;P=0.040)、停药前缓解持续时间>3年(OR 0.231,95% CI:0.058,0.920;P=0.038)为复发的保护因素。

临床怎么用

  • 对达到缓解的LN患者,可考虑在缓解至少3年且维持抗疟药治疗的基础上停用IS。
  • 停用IS后需监测复发,复发患者重启治疗仍可达到缓解。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Whether immunosuppressive therapy may be safely withdrawn in lupus nephritis (LN) is still unclear. We assessed rate and predictors of flare after IS withdrawal in patients with LN in remission. METHODS: Patients with biopsy-proven LN treated with immunosuppressants (IS) between 1980 and 2020 were considered. Remission was defined as normal serum creatinine, proteinuria <0.5 g/24 h, inactive urine sediment, and no extra-renal SLE activity on stable immunosuppressive and/or antimalarial therapy and/or prednisone ≤5mg/day. IS discontinuation was defined as the complete withdrawal of immunosuppressive therapy, flares according to SLEDAI Flare Index. Predictors of flare were analysed by multivariate logistic regression analysis. RESULTS: Among 513 SLE patients included in our database, 270 had LN. Of them, 238 underwent renal biopsy and were treated with IS. Eighty-three patients (34.8%) discontinued IS, 46 (30) months after remission achievement. During a mean (s.d.) follow-up of 116.5 (78) months, 19 patients (22.9%) developed a flare (8/19 renal) and were re-treated; 14/19 (73.7%) re-achieved remission after restarting therapy. Patients treated with IS therapy for at least 3 years after remission achievement had the lowest risk of relapse (OR 0.284, 95% CI: 0.093, 0.867; P = 0.023). At multivariate analysis, antimalarial maintenance therapy (OR 0.194, 95% CI: 0.038, 0.978; P = 0.047), age at IS discontinuation (OR 0.93, 95% CI: 0.868, 0.997; P = 0.040), remission duration >3 years before IS discontinuation (OR 0.231, 95% CI: 0.058, 0.920; P = 0.038) were protective against disease flares. CONCLUSIONS: Withdrawal of IS is feasible in LN patients in remission for at least 3 years and on antimalarial therapy. Patients who experience flares can re-achieve remission with an appropriate treatment.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Zen M, Fuzzi E, Loredo Martinez M, et al. Immunosuppressive therapy withdrawal after remission achievement in patients with lupus nephritis. Rheumatology (Oxford). 2022. PMID: 33909900. doi:10.1093/rheumatology/keab373

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。